1. The use of low-dose immunosuppressive therapy along with pre- and posttransplantation nucleos(t)ide therapy and posttransplantation hepatitis B immunoglobulin (HBIG) has yielded marked improvements in survival. 2. Lamivudine (Epivir-HBV), adefovir (Hepsera), entecavir (Baraclude), tenofovir (Vire
Management of hepatitis B in liver transplant recipients
โ Scribed by Carla S. Coffin; Norah A. Terrault
- Book ID
- 108886070
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 77 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1352-0504
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
To determine the safety and efficacy of ganciclovir usually experience progressive liver disease over an treatment of hepatitis B virus (HBV) infection after liver accelerated time course and pose a difficult managetransplantation, nine patients (seven males, two females; ment challenge. The treatm
Recurrent hepatitis C after liver transplantation is a universal phenomenon. Graft reinfection occurs rapidly; once it is established, allograft cirrhosis and decompensation rapidly ensue in many patients. Treatment with pegylated interferon plus ribavirin is the standard of care among nontransplant
Chronic infection with hepatitis C virus (HCV) is a growing problem worldwide, with up to 300 million individuals infected, and those with chronic infection are at risk for cirrhosis and hepatocellular carcinoma. HCV infection is the most common indication for liver transplantation in the United Sta
Hepatitis E virus (HEV) infection is known to run a self-limiting course. Sporadic cases of acute hepatitis due to infection with HEV genotype 3, present in pig populations, are increasingly recognized. Zoonotic transmission seems infrequent. The entity of unexplained chronic hepatitis after liver t